Tocilizumab has been proposed as a means of opposing hyperinflammatory responses in intensive care patients with COVID-19. Here, we briefly discuss the potentially multiple, synergistic mechanisms whereby tocilizumab might exert therapeutic activity, mostly focusing on the production of tryptophan-derived catabolites that would result from blockade of IL-6 signaling, as contextualized to the cytokine storm occurring in COVID-19 patients.
All Keywords
【저자키워드】 COVID-19, Tocilizumab, Cytokine storm syndrome, tryptophan catabolism, IDO1, 【초록키워드】 mechanism, COVID-19 patients, Hyperinflammatory response, blockade, therapeutic activity, IL-6 signaling, intensive care patient, synergistic, the cytokine storm, with COVID-19, 【제목키워드】 Tryptophan, Potential,
【저자키워드】 COVID-19, Tocilizumab, Cytokine storm syndrome, tryptophan catabolism, IDO1, 【초록키워드】 mechanism, COVID-19 patients, Hyperinflammatory response, blockade, therapeutic activity, IL-6 signaling, intensive care patient, synergistic, the cytokine storm, with COVID-19, 【제목키워드】 Tryptophan, Potential,